Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

@article{Mohty2016RevisedDA,
  title={Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation},
  author={M. Mohty and F. Malard and M. Abecassis and E. Aerts and A. Alaskar and M. Aljurf and M. Arat and P. Bader and F. Baron and A. Bazarbachi and D. Blaise and F. Ciceri and S. Corbacioglu and J. Dalle and F. Dignan and T. Fukuda and A. Huynh and T. Masszi and M. Michallet and A. Nagler and M. N{\'i}Chonghaile and S. Okamoto and A. Pagliuca and C. Peters and F. Petersen and P. Richardson and T. Ruutu and B. Savani and E. Wallhult and I. Yakoub-Agha and R. Duarte and E. Carreras},
  journal={Bone Marrow Transplantation},
  year={2016},
  volume={51},
  pages={906 - 912}
}
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after hematopoietic cell transplantation. Although SOS/VOD progressively resolves within a few weeks in most patients, the most severe forms result in multi-organ dysfunction and are associated with a high mortality rate (>80%). Therefore, careful attention must be paid to allow an early detection of SOS/VOD, particularly as drugs have now proven to be… Expand
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation
TLDR
New diagnostic and severity criteria for SOS/VOD in children on behalf of the European Society for Blood and Marrow Transplantation are proposed. Expand
Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management
TLDR
A group of regional experts have developed a consensus statement on the diagnosis, prevention and management of VOD/SOS in the Middle East and North Africa region to help in the management of HSCT patients in the region. Expand
Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
TLDR
An international consensus guideline for the treatment and prevention of SOS/VOD in adult patients is proposed on behalf of an international expert group. Expand
Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.
  • A. Colecchia, F. Ravaioli, +10 authors F. Bonifazi
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019
TLDR
LSM by TE can be considered a promising method to perform an early, preclinical diagnosis and follow-up of VOD/SOS, and Interestingly, LSM values did not increase significantly in patients experiencing hepatobiliary complications (according to the Common Terminology Criteria) other than VOD /SOS. Expand
Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients
TLDR
It is shown that anicteric VOD/SOS occurs in both adult and pediatric patients post-HCT and can be diagnosed before and after Day 21 in both groups, and the worse survival in patients with bilirubin ≥2 mg/dL suggests requiring hyperbilirubinemia may result in a progressed disease stage associated with worse outcomes. Expand
Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
  • Adrien Picod, Agnès Bonnin, +17 authors M. Mohty
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2018
TLDR
In the experience defibrotide prophylaxis is associated with a low incidence of SOS/VOD after allogeneic HSCT in a high-risk adult population with an acceptable safety profile. Expand
Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party
TLDR
VOD/SOS-related MOF was widely under-reported, accounting for 27% of deaths attributed to MOF of unknown origin without a previous VOD-SOS diagnosis, highlighting the importance of the newly revised EBMT criteria. Expand
New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome.
TLDR
Ultrasound techniques such as a combination of Doppler ultrasound with shear wave elastography and contrast-enhanced ultrasound techniques should be evaluated for diagnosis and follow-up of SOS/VOD. Expand
Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
TLDR
This analysis provides the largest assessment of survival in patients treated with defibrotide for VOD/SOS with or without MOD, and shows survival was 41% and 70%, respectively, for the population of patients receiving any dose of defib rotide. Expand
Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)
TLDR
The very severe grade newly classified by the revised EBMT criteria accounted for the majority of SOS/VOD associated with worse 100-day OS, and intervention should be applied at the latest for moderate to severe SOS/ VOD before deterioration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study
TLDR
It is suggested that irrespective of age, early defibrotide initiation post-VOD/SOS diagnosis may improve Day +100 survival outcomes, although no specific day post-diagnosis provides a clinically meaningful cutoff for better outcome, suggesting that later intervention still retains value if therapy is not initiated sooner. Expand
Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)
TLDR
This review aims to highlight, on behalf of the European Society for Blood and Marrow Transplantation, the current knowledge on SOS/VOD pathophysiology, risk factors, diagnosis and treatments. Expand
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
TLDR
Safety and efficacy resultswere consistent with prior studies of defibrotide in hepatic VOD/SOS, and subgroup analyses lend support to the use of the 25 mg/kg/day dose. Expand
Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
TLDR
It is concluded that a high index of suspicion for VOD should be maintained in patients despite lack of bilirubin elevation in the presence of other diagnostic criteria such as hepatomegaly, abdominal pain, ascites, or weight gain. Expand
Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant
TLDR
Late-onset VOD/SOS may be underrecognized and should be considered in the differential diagnosis of patients undergoing HCT, particularly after high dose busulfan. Expand
How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation
TLDR
A review of transplantation teams' policies regarding preventive measures in high‐risk patients, strict daily control of weight and fluid balance during HCT, homogeneous diagnostic criteria, appropriate complementary studies for a correct differential diagnosis and measures to prevent and manage hepatorenal syndrome based on the author's personal experience. Expand
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
TLDR
The complete response rate, survival to day +100, and absence of significant DF-associated toxicity in this largest patient cohort reported to date confirm the results of earlier studies. Expand
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
TLDR
Defibrotide was associated with significant improvement in day +100 survival and CR rate and the historical-control methodology offers a novel, meaningful approach for phase 3 evaluation of orphan diseases associated with high mortality. Expand
High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation.
  • M. Skeens, J. McArthur, +5 authors R. Bajwa
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2016
TLDR
There is considerable self-reported variability in the diagnosis and management of VOD in children and the practice variations reported in this study should encourage the development of standard practice guidelines, which will be helpful in improving the outcome of this potentially fatal complication. Expand
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
TLDR
The evolution of MOF in the setting of VOD after SCT can be considered a reliable indication of severity and a predictor of poor outcome, and the methods used to evaluate severity are discussed. Expand
...
1
2
3
4
5
...